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Introduction {#sec1}
============

Innate lymphoid cells (ILCs) play roles in homeostasis and responses to injury and infection ([@bib8], [@bib12], [@bib41]). ILC subtypes can react rapidly *in situ* to tissue-associated microenvironmental cues, such as those released upon perturbation of mucosal barrier surfaces. The ILC subgroups mirror T helper subsets based on their principal transcription factor (TF) expression and predominant cytokine secretion: ILC1s express T-bet (encoded by *Tbx21*) and produce IFN-γ; ILC2s express high amounts of Gata3 (encoded by *Gata3*) and secrete IL-5 and IL-13; whereas ILC3s express Retinoic-acid-receptor-related orphan nuclear receptor γ (RORγt) (encoded by *Rorc*) and produce IL-17 and IL-22 ([@bib8], [@bib41]). Furthermore, the previously defined IFN-γ-producing natural killer (NK) cells are closely related to ILC1s but require the TF Eomes for their development, and have profound cytolytic activity ([@bib8], [@bib41]). ILC1 and NK cells share several surface markers, such as NK1.1 and NKp46. NK subpopulations can also vary within and between tissues, and their classification with regard to ILC1 can prove challenging. It has been suggested that ILC1s, ILC2s, and ILC3s are the innate counterparts of CD4^+^ T cells, whereas NKs are the innate manifestation of cytolytic CD8^+^ T cells.

The similarities with T cells also extend to the plasticity of ILC subsets ([@bib8], [@bib41]). Thus, depending on tissue microenvironment and inflammatory context, a fraction of ILCs can modulate their cytokine secretion after the differential expression of cytokine-regulating TFs. It has been reported that, in humans, circulating ILC progenitors represent a pool of uncommitted cells with the capacity to acquire the requisite TF and cytokine profiles as they mature in the tissue ([@bib24]). However, defined ILC progenitors can develop in the bone marrow, and circulating naive ILC subsets have also been reported ([@bib21], [@bib27]).

ILC and NK development has been studied extensively in mice ([@bib7], [@bib9], [@bib11], [@bib17], [@bib20], [@bib45], [@bib49], [@bib51]). ILC and NK differentiation requires the expression of inhibitor of DNA binding 2 (Id2) to repress E-box proteins that would otherwise result in T or B cell commitment from common lymphoid progenitors (CLPs). Current models for the differentiation of ILCs from CLPs have suggested a progression of ever more restricted progenitors defined by their cell surface marker and TF expression. However, there is considerable overlap in the phenotypes of these proposed progenitor populations. The earliest ILC progenitors have been defined by the expression of T cell factor 1 (TCF1), TOX, nuclear factor interleukin 3 regulated (NFIL3), alpha4beta7 integrin (α4β7), and Gata3; the early innate lymphoid progenitor (EILP) expresses little or no Id2 or interleukin-7 receptor α (IL-7Rα) ([@bib15], [@bib48]), and the α-lymphoid precursor (αLP) is Id2^+^ and IL-7Rα^+^ ([@bib49]). EILP and αLP can give rise to NK cells and ILCs. Downstream of these, and reportedly associated with the loss of NK potential, is the common helper-like innate lymphoid progenitor (CHILP) (lineage^−^Id2^hi^IL-7Rα^+^Id2^+^Flt3^−^α4β7^hi^PLZF^+/−^) ([@bib20]) that gives rise to lymphoid tissue inducer (LTi) cells, and the more restricted common ILC progenitor (CILP or ILCP) (lineage^−^Id2^hi^IL-7Rα^+^Flt3^−^α4β7^hi^PLZF^+^) that produces cells committed to one of the "helper" ILC subsets ILC1, ILC2, and ILC3 ([@bib9], [@bib20]). In addition, gene expression analysis of these proposed progenitors indicates that programmed cell death protein-1 (PD-1) is expressed specifically by promyelocytic leukemia zinc finger (PLZF)^+^ ILCP ([@bib37]), and is a marker of committed ILC progenitors ([@bib51]), but is not essential for ILC development ([@bib37]). By contrast, several factors have been demonstrated to play roles during the multipotent phases of ILC commitment ([@bib7], [@bib6], [@bib15], [@bib20], [@bib22], [@bib49], [@bib52]), whereas others appear preferentially important for the development of specific ILC subsets, for example the ILC2 progenitor (ILC2P) requires RAR-related orphan receptor α (RORα) ([@bib14], [@bib45]) and Bcl11b ([@bib3], [@bib43], [@bib50]) for its development.

Progress in this area requires the identification, isolation, and characterization of developmental intermediates in order to ascertain their lineage potential and gene expression state. Identification of transitional states is challenging due to the restricted repertoire of cell surface molecules and lack of characteristic markers. Thus, to define intermediate ILC developmental states during lineage segregation in a physiological context, we generated and inter-crossed reporter mouse strains that allow the simultaneous delineation of five key ILC transcription factors, Id2, Bcl11b, Gata3, RORα, and RORγt, in combination with cell surface markers. This approach revealed highly heterogeneous ILC progenitors and allowed for the unprecedented enrichment of specific TF-defined ILCs to facilitate single-cell transcriptomic analysis, leading us to re-evaluate the existing models for ILC differentiation in bone marrow.

Results {#sec2}
=======

Generation of Compound Transcription Factor Reporter Mice to Define ILC Lineage Development {#sec2.1}
-------------------------------------------------------------------------------------------

To facilitate the identification and isolation of ILC progenitor populations, we generated four reporter mouse strains to trace the expression of the key ILC-associated transcription factors: Id2, Gata3, RORα, and RORγt. Spectrally compatible reporter proteins were selected to enable the generation of compound reporter mice. With the exception of the *Rorc* allele, in which the gene-encoding Katushka (Kat) fluorescent protein was targeted to the translation initiation site for *Rorc* to ensure specificity for the RORγt isoform (Rorc-Kat protein, *Rorc*^Kat^ allele) ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B), all other TF reporter alleles comprised a short C-terminal epitope tag, followed by a reporter protein cloned downstream of a T2A self-cleaving peptide. This ensured that the reporter protein was produced stoichiometrically with the endogenous TF: Id2-Blue fluorescent protein (*Id2*^BFP^ allele) ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B), Gata3-human CD2 (hCD2) (*Gata3*^hCD2^ allele) ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), and Rora-Teal fluorescent protein (*Rora*^Teal^ allele) ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B).

Rorc-Kat was expressed in LTi cells, NKp46^+^NK1.1^−^ ILC3s and the majority of NKp46^+^NK1.1^+^ ILCs, representing "ILC1 or ex-ILC3" ([Figures 1](#fig1){ref-type="fig"}A and 1B). ILC2 did not express Rorc-Kat ([Figures 1](#fig1){ref-type="fig"}A and 1B). As described previously for *Rorc*^GFP/GFP^ mice ([@bib11]), homozygous *Rorc*^Kat/Kat^ mice (which no longer express RORγt) were devoid of peripheral lymph nodes and Peyer's patches (data not shown) lacked ILC3 and LTi cells ([Figure S1](#mmc1){ref-type="supplementary-material"}C) and exhibited impaired T cell differentiation consistent with *Rorc* expression in double-positive thymocytes ([Figures S1](#mmc1){ref-type="supplementary-material"}D--S1F). *Rorc*^+/Kat^ mice had an increased frequency of NKp46^+^NK1.1^+^ "ILC1 or ex-ILC3" cells in small intestine lamina propria (siLP), consistent with the reported role for RORγt in regulating the balance between ILC3 and ex-ILC3 subsets ([@bib42]) ([Figure S1](#mmc1){ref-type="supplementary-material"}C). A small Rorc-Kat^−^ cell subset was also present in the NKp46^+^NK1.1^+^ gate, presumably representing ILC1s or ex-ILC3s ([Figure S1](#mmc1){ref-type="supplementary-material"}G). Analysis of the analogous NKp46^+^NK1.1^+^ cell compartment in *Rorc*^Kat/Kat^ mice highlighted the presence of Rorc-Kat^+^ cells, which might represent ILC1s in which the *Rorc* locus is being transcribed, but from which functional RORγt protein cannot be produced ([Figure S1](#mmc1){ref-type="supplementary-material"}G).Figure 1Generation of Compound 5x polychromILC TF Reporter Mice to Define ILC Lineage Development(A) Flow-cytometry gating strategy for ILC subsets in siLP from TF reporter mice (ILC1 or ex-ILC3: CD45^+^Lin^−^IL-7Rα^+^CD4^−^KLRG1^−^NKp46^+^NK1.1^+^; ILC2: CD45^+^Lin^−^IL-7Rα^+^CD4^−^KLRG1^+^; ILC3: CD45^+^Lin^−^IL-7Rα^+^CD4^−^KLRG1^−^NKp46^+^NK1.1^−^; CD4^−^LTi: CD45^lo^Lin^−^IL-7Rα^+^CD4^−^KLRG1^−^NKp46^−^NK1.1^−^CCR6^+^; CD4^+^LTi: CD45^lo^Lin^−^IL-7Rα^+^KLRG1^−^CD4^+^CCR6^+^).(B) Flow-cytometry analysis of Rorc-Kat expression in the ILC subsets of the siLP of *Rorc*^+/Kat^ mice.(C) Flow-cytometry analysis of Id2-BFP expression in the ILC subsets of the siLP of *Id2*^+/BFP^ mice.(D) Flow-cytometry analysis of Gata3-hCD2 expression in the ILC subsets of the siLP of *Gata3*^*+/*hCD2^ mice.(E) Flow-cytometry analysis of Rora-Teal expression in the ILC subsets of the siLP of *Rora*^+/Teal^ mice.(F) Schematic for generation of *Id2*^+/BFP^*Gata3*^*+/*hCD2^*Rora*^+/Teal^*Bcl11b*^+/tdTom^*Rorc*^+/Kat^ 5x polychromILC mice.(G) Flow-cytometric comparison of the ILC subsets in siLP of *Id2*^+/BFP^*Gata3*^*+/*hCD2^*Rora*^+/Teal^*Bcl11b*^+/tdTom^ (4x polychromILC) mice and *Id2*^+/BFP^*Gata3*^*+/*hCD2^*Rora*^+/Teal^*Bcl11b*^+/tdTom^*Rorc*^+/Kat^ (5x polychromILC) mice.Data are representative of 2 independent experiments; mean ± SEM; not significant (ns), ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; one-way ANOVA with Tukey's post*-*hoc test. Please also see [Figures S1--S4](#mmc1){ref-type="supplementary-material"}.

Phenotypic analysis of the individual *Id2*^BFP^, *Gata3*^hCD2^, and *Rora*^Teal^ strains revealed minimal perturbation to hematopoietic cell populations ([Figures 1](#fig1){ref-type="fig"}A and [S2--S4](#mmc1){ref-type="supplementary-material"}). Consistent with previous reports of *Id2* reporter strains ([@bib18], [@bib20]), *Id2*-BFP expression was observed in all mature ILC subsets, LTi cells, and NK cells ([Figures 1](#fig1){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C), and gene targeting had no discernible effect on the frequency of the leukocyte populations analyzed ([Figures S2](#mmc1){ref-type="supplementary-material"}D--S2F). Gata3-hCD2 expression was observed in all ILC subsets, being highest in ILC2, and intermediate in all other subsets, consistent with previous reports ([@bib28], [@bib32], [@bib38], [@bib47]) ([Figures 1](#fig1){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}C). Analysis of *Gata3*^*+/*hCD2^ and *Gata3*^hCD2/hCD2^ mice indicated little effect on ILC2 frequency or cytokine production after IL-33 challenge ([Figures S3](#mmc1){ref-type="supplementary-material"}D and [S3](#mmc1){ref-type="supplementary-material"}E). All other lymphoid populations examined were unaffected with the exception of a modest increase in the frequency of siLP ILC2s in *Gata3*^hCD2/hCD2^ mice ([Figures S3](#mmc1){ref-type="supplementary-material"}F--S3I).

As anticipated from the critical role for RORα in ILC2 development ([@bib14], [@bib45]), Rora-Teal was expressed in mature ILC2s and committed bone marrow ILC2Ps ([Figures 1](#fig1){ref-type="fig"}E, [S4](#mmc1){ref-type="supplementary-material"}C, and S4D). Although *Rora* gene targeting had no discernible effect on the frequency of mature ILC2s in naive mice, or the expansion and cytokine production of ILC2s upon IL-33 stimulation *in vivo* ([Figures S4](#mmc1){ref-type="supplementary-material"}E--S4G), we noted a reduction in ILC2Ps in *Rora*^Teal/Teal^ mice ([Figure S4](#mmc1){ref-type="supplementary-material"}H), but not in the frequency of CLPs or CHILPs (data not shown). ILC populations in siLP were unperturbed in *Rora*^Teal/Teal^ mice with the exception of ILC3s, which showed a modest skewing toward an NK1.1^+^ "ILC1 or ex-ILC3" phenotype ([Figure S4](#mmc1){ref-type="supplementary-material"}I). All other lymphocyte populations analyzed were normal ([Figure S4](#mmc1){ref-type="supplementary-material"}J).

To analyze ILC progenitors, we inter-crossed the four individual TF reporter mouse strains and additionally incorporated a Bcl11b-tdTomato reporter mouse (Bcl11b-tdTom protein, *Bcl11b*^tdTom^ allele), an important determinant of ILC2 transcriptional programs ([@bib43], [@bib50]) ([Figure 1](#fig1){ref-type="fig"}F). To minimize the influence of altering gene expression through gene targeting, we analyzed compound heterozygotes. Analysis of individual ILC populations from *Id2*^+/BFP^*Gata3*^*+/*hCD2^*Rora*^+/Teal^*Bcl11b*^+/tdTom^ mice indicated that ILC development was unperturbed ([Figure 1](#fig1){ref-type="fig"}G). Introduction of the *Rorc*^+/Kat^ allele to give *Id2*^+/BFP^*Gata3*^*+/*hCD2^*Rora*^+/Teal^*Bcl11b*^+/tdTom^*Rorc*^+/Kat^ "5x polychromILC" mice revealed a modest increase in the frequency of the NKp46^+^NK1.1^+^ and NKp46^+^NK1.1^−^ ILC subsets and a reduction in LTi cells ([Figure 1](#fig1){ref-type="fig"}G).

Thus, we have generated a panel of individual ILC-associated TF reporter mice that can be intercrossed to produce a combinatorial 5x polychromILC strain for analysis of ILC progenitor development. These mice allow for the specific isolation of viable TF^+^ cell subsets that constitute an extremely minor proportion of bone marrow hematopoietic cells and that can be further analyzed by using *in vitro* assays, *in vivo* adoptive transfers, and single-cell gene expression profiling.

Rora-Teal Expression Distinguishes between ILCs and NK Cells {#sec2.2}
------------------------------------------------------------

Rora-Teal in the context of the 5x polychromILC mice revealed that Rora is highly expressed in all ILC populations (data not shown), including siLP Rorc-Kat^−^ ILC1s or ex-ILC3 cells, but not NK cells ([Figures 2](#fig2){ref-type="fig"}A and 2B). To establish whether Rora-Teal expression discriminated ILCs from NK cells, we characterized its expression in NK and ILC1s in spleen, liver, and siLP ([Figure 2](#fig2){ref-type="fig"}C), as defined previously ([@bib35], [@bib44]). In all tissues, Rora-Teal correlated positively with the ILC1-associated markers CD200R, CD61, IL-7Rα, and CD49a, and negatively with the NK-cell-associated markers CD49b, CD62L, and CD11b ([Figure 2](#fig2){ref-type="fig"}C), confirming that *Rora*-Teal was ILC1 restricted. Furthermore RORα-expressing cells were also T-bet^+^ and Eomes^−^, consistent with their classification as ILC1s ([Figures 2](#fig2){ref-type="fig"}D--2F and [S4](#mmc1){ref-type="supplementary-material"}K). A third group of IL-7Rα^−^ cells was RORα^−^ and showed a hybrid phenotype that varied considerably between tissues, similar to CD11c^+^ IFNγ-producing NK cells reported previously in the liver after infection ([@bib2]).Figure 2Rora-Teal Expression Distinguishes ILCs from NK Cells(A) Flow-cytometry gating strategy for ILC1 or ex-ILC3 in the siLP of 5x polychromILC mice.(B) Flow-cytometry analysis of Rora-Teal expression in splenic NK cells (CD3^−^CD19^−^NKp46^+^NK1.1^+^) and siLP ILC1or exILC3 (gated as shown in A) from 5x polychromILC mice.(C) Flow-cytometry analysis of the indicated cell surface markers in Lin^−^NKp46^+^NK1.1^+^ cells from the spleen, liver, and siLP of *Rora*^+/Teal^ mice.(D) Flow-cytometry analysis of CD11c, Eomes, and T-bet expression in NK or ILC1 cells from the spleen of *Rora*^+/Teal^ mice.(E) Flow-cytometry analysis of CD11c, Eomes, and T-bet expression in NK or ILC1 cells from the liver of *Rora*^+/Teal^ mice.(F) Flow-cytometry analysis of CD11c, Eomes, and T-bet expression in NK or ILC1 cells from the siLP of *Rora*^+/Teal^ mice.Data are representative of 2 independent experiments.

Adoptive Transfer of 5x-polychromILC-Derived Bone Marrow Cells Identifies Heterogeneous Multipotent ILC Progenitors {#sec2.3}
-------------------------------------------------------------------------------------------------------------------

As reported previously, Bcl11b expression in the lineage^−^Id2^+^ subset of bone marrow cells defines a population of ILC2-committed cells ([@bib43]). Using the 5x polychromILC mice, we purified specific progenitor populations on the basis of defined TF reporters and characteristic cell surface receptors. We excluded cells expressing lineage markers (Lin^−^) (see [Method Details](#sec4.3){ref-type="sec"}), then gated for IL-7Rα^+^Id2-BFP^+^ cells, before delineating four populations on the basis of CD25 and Bcl11b-tdTom expression ([Figure 3](#fig3){ref-type="fig"}A). The Gata3^hi^ population I (PopI) (Id2^+^Bcl11b^+^CD25^+^) when transferred into sub-lethally irradiated *Rag2*^−/−^*Il2rgc*^−/−^ mice gave rise exclusively to ILC2 progeny ([Figures 3](#fig3){ref-type="fig"}B--3D). Thus, ILC2 potential correlated with acquisition of CD25 and Bcl11b^+^. However, there were smaller cell populations within the Lin^−^Id2^+^ subset that expressed only one, or neither, of these markers ([Figure 3](#fig3){ref-type="fig"}A). We analyzed their expression of additional TFs, defined by 5x polychromILC mice, and expression of α4β7, which has been reported previously to identify a CHILP (Lin^−^IL-7Rα^+^Id2^+^Flt3^−^α4β7^hi^) from which NK cells were not derived ([@bib20]). PopII (Id2^+^Bcl11b^−^CD25^+^) was also Gata3^hi^ and α4β7^int^ ([Figure 3](#fig3){ref-type="fig"}B) and, like PopI, only gave rise to ILC2 progeny upon transfer into *Rag2*^−/−^*Il2rgc*^−/−^ recipients ([Figures 3](#fig3){ref-type="fig"}C and 3D), despite their lack of expression of the Bcl11b-tdTom reporter. Although it is possible that these cells were truly Bcl11b^−^, it is also feasible that they expressed only the non-reporter allele of *Bcl11b* as a result of the stochastic nature of Bcl11b expression as reported during T cell development ([@bib29]). Following adoptive transfer, around 50% of the progeny of PopII upregulated td-Tomato expression, suggesting that this "window" for *Bcl11b* allele activation remained open at the CD25^+^ ILC2P stage of ILC differentiation ([Figure 3](#fig3){ref-type="fig"}E and data not shown). Notably, subsets that already expressed the Bcl11b reporter allele did not subsequently switch this off, and progeny of *Bcl11b*-tdTom^+^ cells remained tdTomato^+^.Figure 3Identification of Heterogeneous Multipotent ILC Progenitors in the Bone Marrow(A) Representative flow-cytometry gating strategy for the characterization and purification of ILC progenitor subsets (populations I, II, III^lo^, III^hi^, IV^lo^, and IV^hi^) (see [Table S1](#mmc1){ref-type="supplementary-material"}) from the bone marrow of 5x polychromILC mice.(B) Flow-cytometry gating strategy for the characterization and purification of ILC progenitor subsets (see A) from the bone marrow of 5x polychromILC mice.(C) Flow-cytometry gating strategy for ILC subsets in siLP arising from adoptive transfer of bone marrow progenitor populations from 5x polychromILC mice into sublethally irradiated *Rag2*^−/−^*Il2rgc*^−/−^ recipients.(D) Flow-cytometry analysis of the ILC progeny generated *in vivo* after the individual adoptive transfers of progenitor cell populations (see A), purified from the bone marrow of 5x polychromILC mice, into *Rag2*^−/−^*Il2rgc*^−/−^ recipients.(E) Proportion of Bcl11b^−^ ILC2 progeny in siLP, derived from the adoptive transfer of purified cell populations (see A) into *Rag2*^−/−^*Il2rgc*^−/−^ recipients. Statistical comparison to ILC2s from a 5x polychromILC mouse.Data are pooled from 2 independent experiments and represent mean ± SEM of 3--11 mice per group; ^∗∗∗∗^p \< 0.0001 one-way ANOVA with Dunnett's post hoc test.

Among Bcl11b-tdTom^+^ cells, there was also a population that was CD25^−^. PopIII (Id2^+^Bcl11b^+^CD25^−^) could be subdivided into a Gata3^hi^α4β7^int^ subset (III^hi^) and a Gata3^lo^α4β7^lo^ subset (III^lo^) ([Figures 3](#fig3){ref-type="fig"}A and 3B). When transferred into recipients, PopIII^hi^ was ILC2 restricted ([Figure 3](#fig3){ref-type="fig"}D). However, PopIII^lo^ produced mixed progeny including NK cells (defined as NKp46^+^NK1.1^+^RORγt^−^Gata3^lo^RORα^−^) ([Figure 3](#fig3){ref-type="fig"}C), ILC2s, and small numbers of ILC1s and ILC3s ([Figure 3](#fig3){ref-type="fig"}D). Thus, despite expressing Bcl11b, these cells were not uniformly ILC2-committed and appear to represent a multipotent progenitor, or a mixed population of cells committed to various NK and ILC lineages. PopIV (Id2^+^Bcl11b^−^CD25^−^) was further divided into a Gata3^hi^α4β7^mix^IV^hi^ subpopulation and a Gata3^lo^α4β7^mix^IV^lo^ subset ([Figure 3](#fig3){ref-type="fig"}B). The adoptive transfer of PopIV^hi^ generated predominantly ILC2s with a minority of ILC3s, whereas the PopIV^lo^ produced mixed progeny constituting ILC2, ILC3, and NK cells and relatively few ILC1s ([Figure 3](#fig3){ref-type="fig"}D).

These results indicate that there are two, or potentially three (i.e., PopII), populations of committed ILC2 progenitors in which the expression of Bcl11b in conjunction with the high expression of Gata3 is associated with ILC2 commitment. When only one of these factors is upregulated, the cells retain multipotency and give rise to NK cells and all ILC populations.

CHILP-Related Cells Indicate Additional ILC Progenitor Heterogeneity {#sec2.4}
--------------------------------------------------------------------

Having identified multiple populations of ILC progenitors that were not committed to any particular ILC lineage, we examined their transcription factor expression in more detail. We first gated on Lin^−^IL-7Rα^+^Id2^+^ cells then subsetted these on the basis of Bcl11b-tdTom expression with the Bcl11b^−^CD25^−^ cells being equivalent to PopIV and the Bcl11b^+^ cells being divided into PopI and PopIII on the basis of CD25 expression ([Figure 4](#fig4){ref-type="fig"}A). Within the Bcl11b^−^CD25^−^ PopIV progenitors, we identified α4β7^hi^ CHILPs and noted that the majority of these cells co-expressed Gata3-hCD2 and Rora-Teal, PD-1, and PLZF, indicating the existence of ILCPs ([Figure 4](#fig4){ref-type="fig"}B). Accordingly, these Gata3-hCD2^+^Rora-Teal^+^ ILCPs (also identified herein as PopIVa cells) produced all ILC lineages, but also Rora-Teal^−^ NK cells ([Figure 4](#fig4){ref-type="fig"}C). The majority of Bcl11b^−^CD25^−^α4β7^lo^ cells were also Gata3-hCD2^+^Rora-Teal^+^ (PopIVb) and, like IVa, gave rise to mixed progeny of all ILC lineages and NK cells ([Figures 4](#fig4){ref-type="fig"}A and 4C). A small fraction (1%--2%) of these Lin^−^IL-7Rα^+^Id2^+^Bcl11b^−^CD25^−^Gata3^hi^α4β7^lo^ cells expressed Rorc-Kat (PopIVc), although this had minimal effect on the progeny obtained from adoptive transfer ([Figures 4](#fig4){ref-type="fig"}A and 4C). Rorc-Kat expression within PopIII^lo^ was designated PopIII^lo-kat+^: Lin^−^IL-7Rα^+^Id2^+^Bcl11b^+^CD25^−^Gata3^lo^α4β7^int^RORγt^+^ ([Figure 4](#fig4){ref-type="fig"}A). Notably, adoptive transfer of PopIII^lo-kat+^ generated primarily ILC3s and ILC2s and very few ILC1s or NK cells ([Figure 4](#fig4){ref-type="fig"}D). We were unable to identify LTi-like cells, as defined by CCR6 expression, from any of the populations analyzed (data not shown).Figure 4ILCP-Related Cells Indicate Additional ILC Progenitor Heterogeneity(A) Alternative gating strategy for the characterization and purification of populations I, III, and IV from 5x polychromILC bone marrow, to identify Rorc-Kat-positive and -negative progenitors (populations IVa, IVb, IVc, and III^lo-kat+^) (see [Table S1](#mmc1){ref-type="supplementary-material"}).(B) Flow-cytometry analysis of Gata3-hCD2, α4β7, PD-1, PLZF (intracellular stain \[ICS\]), and Rora-Teal expression within gate IVa (Lin^−^IL-7Rα^+^Id2^+^CD25^−^α4β7^hi^), which corresponds with CHILP (Lin^−^IL-7Rα^+^Id2^+^Flt3^−^α4β7^hi^). The green gate represents Gata3^hi^ subset (Pop IVa); the red gate represents Gata3^lo^ subset.(C) Flow-cytometry analysis of siLP to identify ILC progeny generated *in vivo* after the individual adoptive transfers of progenitor cell populations IVa, IVb, and IVc, purified from the bone marrow of 5x polychromILC mice, into *Rag2*^−/−^*Il2rgc*^−/−^ recipients.(D) Flow-cytometric characterization of progenitor cell subpopulation III^lo-kat+^ and analysis of the ILC progeny in siLP after the adoptive transfer of III^lo-kat+^ progenitors, purified from the bone marrow of 5x polychromILC mice, into *Rag2*^−/−^*Il2rgc*^−/−^ recipients.Data are pooled from 2--4 independent experiments and represent mean ± SEM of 6--14 mice per group.

Together, these results demonstrate that ILCPs, or at least a proportion of ILCPs (or CHILPs), retain the capacity to generate NK cells. Furthermore, 5x polychromILC mice allowed us to identify ILCP-related populations that also generated NK cells and all ILC subsets. Notably, the introduction of the Rorc-Kat reporter enabled the identification of a progenitor with greater restriction to the ILC3 lineage.

*Zbtb16*-tdTom Reporter Reveals Fluctuating Expression throughout Hematopoiesis {#sec2.5}
-------------------------------------------------------------------------------

It has been reported that PLZF (encoded by *Zbtb16*) expression identifies a subset of CHILPs that are ILC restricted, designated ILCPs, and that LTi cells appear to have no history of PLZF expression as indicated via a *Zbtb16* fate-map and reporter approach, suggesting they originated from a putative PLZF^−^ ILC progenitor ([@bib9]). We generated a Zbtb16-tdTom reporter (*Zbtb16*^tdTom^ allele) with the tdTomato protein expressed downstream of a self-splicing T2A sequence ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B), in direct relation to PLZF protein ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Analysis of progenitors in the bone marrow and mature ILCs in the siLP indicated no significant effects on the proportions of these cells because of gene targeting ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E). Although NKT and NK cells were reduced in *Zbtb16*^tdTom/tdTom^ mice, no detectable changes were observed in immune cell populations measured in the *Zbtb16*^tdTom/+^ mice subsequently used in experiments ([Figures S5](#mmc1){ref-type="supplementary-material"}F and S5G). Zbtb16-tdTom was found to be highly expressed in all CHILPs (Lin^−^IL-7Ra^+^Id2^+^Flt3^−^α4β7^hi^) ([Figures 5](#fig5){ref-type="fig"}A and 5B). Furthermore, contrary to a previous report ([@bib9]), we found Zbtb16-tdTom in all LTi cells (including fetal LTi), ILC1s, and ILC3s present in the siLP, but not in the majority of mature ILC2s ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}H). Zbtb16-tdTom reporter expression was also detected in most hematopoietic stem cells (HSCs) ([Figures 5](#fig5){ref-type="fig"}A and 5D), but not CLPs ([Figures 5](#fig5){ref-type="fig"}A and 5E), indicating fluctuating *Zbtb16* gene expression during hematopoiesis, and expression was also detected in ILC2Ps ([Figures 5](#fig5){ref-type="fig"}A and 5F).Figure 5Zbtb16-tdTom Reporter Reveals Fluctuating Expression throughout Hematopoiesis(A) Flow-cytometric gating strategy for HSC, CLP, CHILP, and ILC2P subsets in *Zbtb16*^+/tdTom^ bone marrow.(B) Flow-cytometric analysis of Zbtb16-tdTom in bone-marrow-derived CHILP (Lin^−^CD45^+^IL-7Rα^+^α4β7^hi^Sca1^int/lo^Flt3^−^CD25^−^).(C) Flow-cytometry analysis of Zbtb16-tdTom expression in the ILC subsets in the siLP of *Zbtb16*^*+/*tdTom^ mice.(D) Flow-cytometry analysis of Zbtb16-tdTom expression in bone marrow-derived HSCs (Lin^−^CD45^+^Kit^+^Sca1^+^Flt3^−^).(E) Flow-cytometry analysis of Zbtb16-tdTom expression in bone-marrow-derived CLPs (Lin^−^CD45^+^ IL-7Rα^+^Flt3^+^).(F) Flow-cytometry analysis of Zbtb16-tdTom expression in bone-marrow-derived ILC2Ps (Lin^−^CD45^+^IL-7Rα^+^α4β7^+^Sca1^hi^Flt3^−^CD25^+^).Data are representative of 2 independent experiments. Please also see [Figure S5](#mmc1){ref-type="supplementary-material"}.

*In vitro* Cell Differentiation Analysis Identifies Multipotent and ILC3-Restricted ILC Progenitors {#sec2.6}
---------------------------------------------------------------------------------------------------

To complement the *in vivo* adoptive transfer studies, we performed *in vitro* ILC progenitor differentiation assays by using purified progenitor subpopulations from the 5x polychromILC mice. 5x-polychromILC-defined progenitor subsets were co-cultured on OP9 stromal cells with IL-7 and stem cell factor (SCF) to assess their lineage potential ([Figure 6](#fig6){ref-type="fig"}A). *In vitro* culture of PopI produced ILC2s (data not shown). However, far greater lineage diversity was observed when assessing the progeny from PopIII and PopIV, similar to results obtained *in vivo*. Cultures of progenitor subsets PopIVa and PopIVb both gave rise predominantly to NK and ILC1 cells and fewer ILC2s and almost no ILC3s ([Figures 6](#fig6){ref-type="fig"}B and 6C). PopIVc expressing Rorc-Kat produced almost equivalent proportions of ILC3 and NK or ILC1 cells ([Figure 6](#fig6){ref-type="fig"}C). Analysis of PopIII^hi^ and PopIII^lo^ essentially recapitulated the adoptive transfer data, with PopIII^hi^ generating ILC2s and PopIII^lo^ leading to mixed NK and/or ILC1, ILC2, and ILC3 progeny ([Figure 6](#fig6){ref-type="fig"}D). PopIII^lo-kat+^ cells were committed almost exclusively to generating Rorc-Kat^+^ ILC3s ([Figure 6](#fig6){ref-type="fig"}D).Figure 6*In Vitro* Analysis Identifies Multipotent and ILC3-Restricted ILC Progenitors(A) Schematic of purified bone marrow progenitor populations co-cultured *in vitro* with OP9 stromal cells to facilitate ILC development.(B) Representative flow-cytometry gating strategy for ILC subsets generated *in vitro* after co-culture of progenitor cell populations, purified from the bone marrow of the 5x polychromILC mice, with OP9 stromal cells.(C) Flow-cytometry analysis of the proportions of ILC subsets generated *in vitro* after co-culture of progenitor cell populations IVa, IVb, and IVc, purified from the bone marrow of 5x polychromILC mice, with OP9 stromal cells.(D) Flow-cytometry analysis of the proportions of ILC subsets generated *in vitro* after co-culture of progenitor cell populations III^hi^, III^lo^, and III^lo-kat+^, purified from the bone marrow of 5x polychromILC mice, with OP9 stromal cells.(E) Characterization of progeny derived from clonal analysis of single IVa, IVb, and IVc progenitor cells, purified from the bone marrow of 5x polychromILC mice, after co-culture with OP9 stromal cells.(F) Characterization of progeny derived from single III^hi^, III^lo^, and III^lo-kat+^ progenitor cells, purified from the bone marrow of 5x polychromILC mice, after co-culture with OP9 stromal cells.(G) Proportion of Eomes^+^ (NK) and Eomes^−^ (ILC1) cells after co-culture of the indicated progenitor populations, purified from the bone marrow of 5x polychromILC mice, with OP9 stromal cells.(H) Flow-cytometric analysis of cells derived from IVa, IVb, and IVc progenitor populations for the expression of Eomes (co-cultured with OP9 stromal cells).(I) Flow-cytometric analysis of cells derived from IVa, IVb, and IVc progenitor populations for the expression of perforin and IFN-γ (co-cultured with OP9 cells and stimulated for 48 hr with IL-2, IL-15, and IL-18).(J) Flow-cytometric analysis of Bcl11b, Eomes, perforin, and IFN-γ expression in LiveCD45.2^+^ spleen cells stimulated *in vitro* with IL-2, IL-15, and IL-18, 6 weeks after transfer of IVa cells into *Rag2*^−/−^*Il2rgc*^−/−^ recipients.(A--D) Data are pooled from 3 independent experiments; mean ± SEM of 5--9 replicate cultures. (E and F) Data are pooled from 3 independent experiments. (G) Data are pooled from 2 independent experiments. (H and I) Data are representative of 3 independent experiments. (J) shows data concatenated from 7 animals taken from 2 independent experiments. Please also see [Figure S6](#mmc1){ref-type="supplementary-material"}.

To address whether the populations giving rise to mixed ILC progeny contained multipotent ILC progenitors or were a mixture of committed cells, we performed single-cell differentiation analysis. The majority of mixed lineage potential cells were located in the Bcl11b^−^ subsets IVa, IVb, and IVc ([Figure 6](#fig6){ref-type="fig"}E). A proportion of single cells from PopIVa (and to a lesser extent PopIVb) gave rise to progeny consisting of a mixture of NK and/or ILC1s and ILC2s ([Figure 6](#fig6){ref-type="fig"}E). PopIVc also contained multipotent progenitors that gave rise to NK and/or ILC1 and ILC2 cells, but additionally harbored individual progenitors with NK and/or ILC1 and ILC3 potential, consistent with their expression of Rorc-Kat ([Figure 6](#fig6){ref-type="fig"}E). By contrast, the Bcl11b^+^PopIII^hi^, PopIII^lo^, and PopIII^lo-kat+^ cells represented lineage-committed precursors ([Figure 6](#fig6){ref-type="fig"}F). The Gata3^hi^ cells (PopIII^hi^) gave rise exclusively to ILC2s, whereas the Rorc^+^ (PopIII^lo-kat+^) cells produced almost entirely ILC3s ([Figure 6](#fig6){ref-type="fig"}F). The remaining Gata3^lo^Rorc^−^ (PopIII^lo^) cells contained committed progenitors for all three ILC lineages ([Figure 6](#fig6){ref-type="fig"}F).

To clarify the proportions of NK cells and ILC1s derived from subsets IVa, IVb, IVc, and III^lo^, we analyzed the expression of Eomes after differentiation in the presence of OP9 stroma. Although all four subsets produced ILC1 progeny ([Figure 6](#fig6){ref-type="fig"}G), NK potential, as determined by Eomes expression, was restricted to subsets IVa, IVb, and IVc ([Figures 6](#fig6){ref-type="fig"}G and 6H). Furthermore, on stimulation *in vitro* with IL-2, IL-15, and IL-18, the Bcl11b^−^ cells from subsets IVa, IVb, and IVc upregulated perforin and IFN-γ expression, whereas the Bcl11b^+^ cells did not ([Figure 6](#fig6){ref-type="fig"}I). The Bcl11b^−^ cells also had the potential to express T-bet ([Figure S6](#mmc1){ref-type="supplementary-material"}A). We also assessed the capacity of progenitor cell populations IVa, IVb, and IVc to give rise to mature NK cells after transfer to *Rag2*^−/−^*Il2rgc*^−/−^ mice. Following engraftment of the donor cells, *ex vivo* stimulation of splenocytes revealed the presence of Eomes, perforin, and IFN-γ^+^ NK cells from PopIVa ([Figure 6](#fig6){ref-type="fig"}J), but not IVb or IVc ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Together these data indicate that the IVa progenitor population retains cell-intrinsic NK potential.

Although both the *in vivo* and *in vitro* approaches have their limitations, the *in vitro* data generally support our *in vivo* result but also demonstrate that in a more restricted environment TF^+^ ILC progenitors might show greater lineage restriction. This is notable with the bias toward ILC1 and NK development observed in PopIVa and IVb, and the propensity of Rorc-Kat^+^ populations to generate ILC3s.

Single-Cell Analysis Identifies the Developmental Divergence of ILC2Ps and Heterogeneous ILC1, ILC3, and NK Progenitors {#sec2.7}
-----------------------------------------------------------------------------------------------------------------------

To further investigate the heterogeneity of the ILC and NK progenitors, we initially purified individual Lin^−^Id2^+^ bone marrow cells (with a small number of Lin^−^Id2^−^ cells also sampled for comparison) and performed single-cell RNA-sequencing (scRNA-seq) to profile progenitor cell gene expression. Subsequently, to obtain sufficient representation of the extremely rare cells, ILC progenitors were isolated as outlined above and summarized in [Table S1](#mmc1){ref-type="supplementary-material"}. Data were then filtered to include only those cells that expressed the genes encoding *Id2* or *Il7ra*. Clustering identified three predominant cell clusters of ILCs and ILC and/or NK progenitors (clusters C1--C3) as shown on a t-distributed stochastic neighbor embedding (tSNE) plot ([Figure 7](#fig7){ref-type="fig"}A), as well as a number of other clusters: C4 and C5 were characterized by the expression of the B cell and/or myeloid gene *Spi1*, whereas C6 expressed the erythroid-specific gene *Gata1*, and a satellite cluster of C2 expressed the γδ T cell-TF *Sox13* (C2a). siLP-derived ILCs were also analyzed to provide comparison to bone marrow samples (clusters C7 and C8). These cells were characterized by the expression of markers more typical of mature ILC2 (cluster C7) or ILC1, ILC3, or NK cells (cluster C8). Analysis of siLP also identified a small cluster of cells expressing immunoglobulin transcripts (C9).Figure 7Single-Cell Analysis Identifies Divergence of ILC2P and Heterogeneous ILC3, ILC1, and NK Progenitors(A) tSNE plot of single-cell gene expression analysis from bone marrow and siLP cells (1,637 individual cells) purified from 5x polychromILC mice. Black circles highlight clusters C1--C3. Dotted line divides cells acquired from siLP (left) and BM (right).(B) Heatmap of selected genes differentially expressed between bone marrow cells not expressing *Spi1*, *Gata1*, or *Sox13* (504 cells, predominately cells in clusters C1--C3).(C) tSNE plots of single-cell gene expression of chemokine receptors in the populations defined above in (A) and (B). Black dots indicate cells expressing \> 5 normalized pseudocounts for the indicated gene; orange dots indicate cells expressing \< 5 normalized pseudocounts for the indicated gene; and light gray dots indicate cells expressing *Spi1*, *Gata1*, or *Sox13*.(D) Cell trajectory from pseudotime analysis of a subset of bone marrow cells not expressing *Spi1*, *Gata1*, or *Sox13* and sequenced with greater read depth (328 cells, predominately cells in clusters C1--C3). Shown is the trajectory from the early progenitor cells located in cluster C1 toward a bifurcation point at which the ILC2P cells (largely cluster C2) and the ILC3, ILC1, and NK cells (largely cluster C3) diverge.(E) Overlay of index-sorted cell phenotype onto the pseudotime trajectory shown in (D). Please also see [Figure S7](#mmc1){ref-type="supplementary-material"}.

Cluster C1 was characterized by the expression of a spectrum of genes previously associated with early progenitor cell identity, including *Zbtb16*, *Pdcd1*, *Tox*, *Tox2*, *Cbfa2t3*, *Kit*, *Sox4*, *Hes1*, *Gata3*, and *Myb* ([Figure 7](#fig7){ref-type="fig"}B). *Cux1* and *Fgf3* were also found to preferentially distinguish cluster C1 ([Figure 7](#fig7){ref-type="fig"}B) but have not previously been linked to ILC development. Cluster C2 was characterized by genes associated with the ILC2 lineage, including *Il17rb*, *Il1rl1*, *Lztfl1*, and high expression of *Gata3* ([Figure 7](#fig7){ref-type="fig"}B). Cluster C3 was characterized by predominantly ILC1-, ILC3-, and NK-related genes ([Figure 7](#fig7){ref-type="fig"}B), indicating a more heterogeneous population and supporting the *in vivo* and *in vitro* progenitor differentiation data. Clustering of expression based on the genes displayed in [Figure 7](#fig7){ref-type="fig"}B largely recapitulated the clustering shown in the tSNE plot ([Figure 7](#fig7){ref-type="fig"}A), suggesting these genes are among the most important in differentiating these cell types. Notably, we observed additional substructure in the gene expression patterns within cluster C3. One subcluster was characterized by the expression of NK-like genes including *Klr* transcripts, the chemokine *Xcl1*, and the absence of *Rora* and *Rorc*. Whereas the other subcluster contained cells expressing *Rora* and *Rorc* and had an absence of *Klr* genes ([Figure 7](#fig7){ref-type="fig"}B). Differential chemokine receptor expression delineated clusters: cells in cluster C1 were predominantly C-X-C motif chemokine receptor 5-positive (*Cxcr5*^+^) but *Cxcr6*^−^, whereas C2 cells expressed principally C-C motif chemokine receptor 9 (*Ccr9*), and *Cxcr3* was largely restricted to C3 ([Figure 7](#fig7){ref-type="fig"}C).

To investigate the potential lineage relationship between the progenitors, we performed pseudotime analysis on the bone marrow ILC and NK progenitors by using data from cells that did not express *Spi1*, *Gata1*, or *Sox13*, and that were sequenced with greater read depth (predominately cells in clusters C1--C3). Using this approach, we identified developmental intermediates along a trajectory from the early progenitor cells located in cluster C1 toward a bifurcation point at which the ILC2Ps (cluster C2) and the putative ILC1, ILC3, and NK progenitors (cluster C3) diverged ([Figure 7](#fig7){ref-type="fig"}D). Furthermore, using index sequencing data captured during sample collection, we mapped the phenotypes of individual cells onto the pseudotime plot ([Figures 7](#fig7){ref-type="fig"}E and [S7](#mmc1){ref-type="supplementary-material"}A). Cluster C2 consisted primarily of cells sorted from population I. The majority of cells in cluster C1 correlated to population IVa, whereas cluster C3 and the transitional states comprised a heterogeneous mix of multiple phenotypes. Altogether these data corroborate our *in vivo* and *in vitro* analyses of NK and ILC developmental potential, demonstrating the existence of Id2^+^ multipotent bone marrow ILC1, ILC3, and NK progenitors. Furthermore, they highlight the heterogeneous potential of the ILC and NK progenitors and how this is distinct from the relatively uniform differentiation of the more frequent ILC2Ps.

Discussion {#sec3}
==========

Multiple TFs have been associated with ILC differentiation and a number of progenitor states, including the EILP, αLP, CHILP, ILCP, and ILC2P, have been defined on the basis of combinations of surface protein and TF reporter expression ([@bib9], [@bib15], [@bib20], [@bib37], [@bib43], [@bib45], [@bib48], [@bib51], [@bib50]). In this study, the generation of 5x polychromILC mice enabled us to delineate bone marrow ILC progenitors on the basis of expression of 5 key ILC-associated TFs: Id2, Bcl11b, Gata3, RORα, and RORγt. This approach enabled the resolution and isolation of rare progenitor cell populations for subsequent analysis of lineage potential and gene expression.

Among the Id2-BFP^+^ bone marrow cells, ILC2Ps were predominant, and Id2-BFP^+^Bcl11b-tdTom^+^Gata3-hCD2^hi^ bone marrow cells gave rise exclusively to ILC2 progeny. Indeed, Bcl11b^+^ and Gata3^hi^ co-expression was sufficient to ensure ILC2 commitment in cells that had not upregulated CD25 (PopIII^hi^). Upregulation of Bcl11b alone was insufficient to drive ILC2 commitment given that Bcl11b^+^Gata3^lo^ cells (III^lo^) retained the capacity to generate all other ILC and NK lineages. A small fraction of this uncommitted Bcl11b^+^Gata3^lo^ cell subset expressed Rorc-Kat (III^lo-kat+^) and had a greater propensity to generate ILC3 upon adoptive transfer and gave exclusively ILC3s upon *in vitro* culture. These elusive cells (approximately 1 cell in a million in the bone marrow) appear to represent the earliest committed ILC3 progenitors in mouse bone marrow, and their discovery demonstrates the utility of our multi-TF-driven approach. Although ILC progenitors might seed the peripheral tissues and differentiate *in situ* to populate the ILC3 niche, our results now raise the possibility that already-committed bone-marrow-derived ILC3 progenitors populate mucosal tissues. Future studies will be needed to determine the relative contributions of these alternative pathways for ILC3 generation.

We also identified a spectrum of multipotent Id2^+^Bcl11b^−^ bone marrow populations that were heterogeneous with respect to α4β7 integrin and Gata3 expression. A major fraction of these cells was α4β7^hi^Gata3^+^ (IVa) and co-expressed PLZF and PD-1 and corresponded to the ILCP reported previously to be an ILC1-, ILC2-, ILC3-restricted progenitor ([@bib9], [@bib15]). However, we observed that in addition to generating ILC1s, ILC2s, and ILC3s, these ILCPs gave rise to a population of Rora-Teal^−^lineage^+^NK1.1^+^NKp46^+^ NK cells that expressed Eomes and perforin, indicating additional lineage potential. Thus ILCP, as currently defined, is not exclusively ILC-lineage restricted but retains some NK lineage potential. A recent report utilizing Id2 and PLZF reporters has also demonstrated that an ILCP population has the potential to differentiate into ILC1, ILC2, ILC3, and NK cells ([@bib46]). We also identified a minor fraction of α4β7^lo^Gata3^+^ ILCP-related cells (IVb), a small proportion of which also expressed Rorc-Kat (IVc) that also gave rise to a population of *Rora*-Teal^−^Lin^+^NK1.1^+^NKp46^+^ NK cells, in addition to ILC1s, ILC2s, and ILC3s. Although a small proportion of α4β7^lo^ ILCP-related cells expressed Rorc-Kat, unlike their Bcl11b^+^ counterparts, these cells showed little propensity for ILC3 restriction after stromal cell co-culture or adoptive transfer. Rather than signifying commitment, Rorc-Kat expression in this instance could reflect the multi-lineage priming reported to occur prior to ILC-lineage commitment during embryogenesis ([@bib17]).

The expression of PLZF has been used to define the transition between CHILP and ILCP ([@bib9], [@bib20]) and has been associated with an ILC-committed progenitor population that has lost the capacity to generate NK cells and LTi. It has been postulated that LTi cells originate from PLZF^−^ progenitors on the basis of cell fate analyses ([@bib46]) and the observation that mature LTi are negative for both fate-mapping and expression reporters in a strain that drives expression of a Cre-GFP fusion protein from the *Zbtb16* promoter as part of a bicistronic allele utilizing an IRES sequence ([@bib9]). However, our data indicate that the vast majority of HSCs, CHILPs, and mature LTi cells are Zbtb16-tdTom^+^. Similarly, EILPs have also been reported to be PLZF^+^ ([@bib15]). It is thus surprising that LTi cells were fate-mapper negative in the PLZF-fm strain ([@bib9]). This discrepancy might reflect a lower expression of the Cre-GFP fusion protein and/or inefficiency of Cre excision of the STOP cassette, which triggers fate-mapping reporter expression, or might be attributable to the requirement to remove FM^+^ bone marrow (BM) cells and reconstitute recipients with FM^−^ cells because of PLZF expression during mouse development ([@bib9]). By contrast, our *Zbtb16*^tdTom^ strain showed a wide dynamic range of reporter expression (CHILPs \> ILC2Ps \> HSCs \> CLPs), which accurately recapitulated the profile of PLZF protein expression determined by intracellular staining. Incorporation of the *Zbtb16*^tdTom^ allele into additional compound reporter strains might help to clarify the role of PLZF in ILC commitment.

Single-cell gene expression analysis of ILC bone marrow progenitors revealed three predominant clusters of cells with distinct ILC-associated gene expression patterns: an early progenitor (C1), an ILC2P population (C2), and a mixed ILC1, ILC3, and NK progenitor population (C3). C1 was characterized by genes associated with early progenitors including *Zbtb16*, *Pdcd1*, *Tox*, *Tox2*, *Kit*, *Sox4*, *Hes1*, *Gata3*, and *Myb* ([@bib1], [@bib7], [@bib11], [@bib17], [@bib22], [@bib36], [@bib45], [@bib51], [@bib52]). Indeed, the widespread expression of *Zbtb16* (PLZF) and *Pdcd-1* (PD-1) in C1 suggests they are ILCPs (population IVa in our analysis). PD-1 has been reported as a marker of PLZF^+^ ILCPs ([@bib37], [@bib51]), though the absence of PLZF ([@bib15]) or PD-1 in mice did not alter ILCP development ([@bib37]). C1 was also characterized by the expression of transcriptional repressors such as core binding factor Cbfa2t3 ([@bib37]) and *Cux1*, a repressor for which there are multiple binding sites in the *Zbtb16* promoter region ([@bib13]) but which has not been linked previously with ILC progenitors. Cluster 2 was clearly ILC2Ps, characterized by the expression of the *Il17rb* and *Il1rl1* encoding the receptors for IL-25 and IL-33 and high amounts of *Gata3* ([@bib14], [@bib51], [@bib52]). *Lztfl1*, the gene encoding leucine zipper transcription-factor-like 1 (LZTFL1), is reported to be expressed in all mature ILC subsets in the small intestine but here was largely restricted to the ILC2Ps. Cluster 3 represented a highly heterogeneous population which shared both ILC1, ILC3, and NK cell gene expression signatures. Two subclusters were present in C3. The putative ILC1 and ILC3 progenitors frequently co-expressed *Tbx21* and *Rorc*, in addition to *Ncr1* (encoding NKp46), suggesting their potential to generate either lineage. The other subcluster was characterized by the expression of *Klr* genes and *Tbx21*, but not *Rorc or Rora*, highlighting their probable commitment to the NK cell lineage. C3 was most clearly delineated from ILCPs and ILC2Ps by the expression of CD7, a cell surface molecule used as a pan-ILC marker in human studies ([@bib24]) that is poorly studied in mouse ILC biology. Although a small number of genes were expressed by most cells in C3, this cluster was otherwise notable for the heterogeneity of gene expression.

Clusters C1, C2, and C3 could be discriminated by their chemokine receptors. As shown previously, CXCR6 expression defines a proportion of EILPs and αLPs ([@bib48], [@bib49]); however, CXCR6^−^ αLPs also appear capable of generating ILCs and NK cells ([@bib49]). Our single-cell analysis indicated that only relatively few cells in cluster C1 expressed *Cxcr6* but that almost all cells in clusters C2 and C3 were *Cxcr*6^+^, indicating that this marker has limited specificity among ILC resident bone marrow progenitors. However, it is notable that the deletion of CXCR6 results in a modest accumulation of ILCPs in the bone marrow ([@bib4]). A recent study reported that *Cxcr5* expression, assessed by bulk cell population gene expression analysis, was absent in αLP, moderately induced in EILP, and highest in ILCPs and surface CXCR5 was detected on ILCPs ([@bib15]). With the benefit of 5x polychromILC mice to enrich, identify, and isolate rare single progenitors, we identified that *Cxcr5* expression was mostly restricted to C1 and there was little to no expression detected in C2 or C3. This suggests that Cxcr5 expression is a useful marker of the ILCPs. However, it is unclear what role CXCR5 is playing in ILC development. CXCR3 has been reported to be expressed on mature ILC1s ([@bib10], [@bib20]), although its role in ILC progenitor biology is unknown. As reported previously, CCR9 is primarily expressed on ILC2Ps ([@bib16]), as we observed in cluster C2 in the bone marrow, and ILC2 homing to the small intestine is impaired in *Ccr9*^−/−^ mice ([@bib19]).

These clusters, defined by gene expression, mirror the bone marrow progenitors identified during the phenotypic characterization of 5x polychromILC mice. Our pseudotime analysis suggests that the switch associated with ILC2 lineage commitment represents a rapid and concerted alteration in gene expression leading to "all-or-nothing" lineage commitment with very few cells representing intermediates along the ILC2P branch. In contrast, many more transition states were located between the early progenitor (ILCP) and putative ILC1, ILC3, and NK progenitors, reflecting the heterogeneity in TF and surface molecule expression that we observed among non-ILC2P bone marrow progenitors. A recent report has described a similar divergence of human ILC2 progenitors from a progenitor with shared NK cell and ILC3 lineage potential ([@bib5]).

Our data support a model whereby EILPs progress directly to the PLZF^+^ ILCP state, then progress through a trans-ILCP intermediate phase before expressing TFs characteristic of lineage-committed progenitors and divergence of ILC2Ps from a common NK, ILC1, and ILC3 developmental pathway ([Figure S7](#mmc1){ref-type="supplementary-material"}B).

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-mouse CD3 (145-2C11)BiolegendCat\#100320; RRID: [AB_312685](nif-antibody:AB_312685){#intref0010}Anti-mouse CD5 (53-7.3)eBioscienceCat\#25-0051-81; RRID: [AB_657755](nif-antibody:AB_657755){#intref0015}Anti-mouse CD4 (GK1.5)eBioscienceCat\#25-0041-82; RRID: [AB_469576](nif-antibody:AB_469576){#intref0020}Anti-mouse CD8 (53-6.7)eBioscienceCat\#25-0081-82; RRID: [AB_469584](nif-antibody:AB_469584){#intref0025}Anti-mouse CD11b (M1/70)BiolegendCat\#101216; RRID: [AB_312799](nif-antibody:AB_312799){#intref0030}Anti-mouse CD11c (N418)eBioscienceCat\#25-0114-82; RRID: [AB_469590](nif-antibody:AB_469590){#intref0035}Anti-mouse CD19 (eBio1D3)eBioscienceCat\#25-0193-82; RRID: [AB_657663](nif-antibody:AB_657663){#intref0040}Anti-mouse FcεRI (MAR-1)eBioscienceCat\#25-5898-82; RRID: [AB_2573493](nif-antibody:AB_2573493){#intref0045}Anti-mouse Ly-6C/Ly-6G (RB6-8C5)eBioscienceCat\#25-5931-82; RRID: [AB_469663](nif-antibody:AB_469663){#intref0050}Anti-mouse TER-119 (TER-119)eBioscienceCat\#25-5921-82; RRID: [AB_469661](nif-antibody:AB_469661){#intref0055}Anti-mouse NK1.1 (PK136)eBioscienceCat\#25-5941-82; RRID: [AB_469665](nif-antibody:AB_469665){#intref0060}Anti-mouse Nkp46 (29A1.4)BiolegendCat\#137619; RRID: [AB_2562452](nif-antibody:AB_2562452){#intref0065}Anti-mouse IFN-γ (XMG1.2)BiolegendCat\#505838; RRID: [AB_2629667](nif-antibody:AB_2629667){#intref0070}Anti-mouse CD16/CD32 (Fc Block) (2.4G2)BioXCellCat\#BE0307; RRID: [AB_2736987](nif-antibody:AB_2736987){#intref0075}Anti-mouse IL-7Rα (SB/199)BiolegendCat\#121104; RRID: [AB_493502](nif-antibody:AB_493502){#intref0080}Anti-mouse CD62L (MEL-14)BiolegendCat\#104438; RRID: [AB_2563058](nif-antibody:AB_2563058){#intref0085}Anti-mouse CD117 (c-Kit) (2B8)BiolegendCat\#105824; RRID: [AB_2131597](nif-antibody:AB_2131597){#intref0090}Anti-mouse IL-5 (TRFK5)BiolegendCat\#504306; RRID: [AB_315330](nif-antibody:AB_315330){#intref0095}Anti-mouse CCR6 (CD196) (29-2L17)BiolegendCat\#129814; RRID: [AB_1877147](nif-antibody:AB_1877147){#intref0100}Anti-mouse CD61 (HMβ3-1)BiolegendCat\#13-0611-81; RRID: [AB_466487](nif-antibody:AB_466487){#intref0105}Anti-mouse I-A/I-E (M5/144.15.2)BiolegendCat\#107636; RRID: [AB_2734168](nif-antibody:AB_2734168){#intref0110}Anti-human CD2 (RPA-2.10)BiolegendCat\#300218; RRID: [AB_2566040](nif-antibody:AB_2566040){#intref0115}Anti-mouse CD45 (30-F11)eBioscienceCat\#56-0451-82; RRID: [AB_891454](nif-antibody:AB_891454){#intref0120}Anti-mouse CD45.2 (104)eBioscienceCat\#56-0454-82; RRID: [AB_657752](nif-antibody:AB_657752){#intref0125}Anti-mouse KLRG1 (2F1)eBioscienceCat\#46-5893-82; RRID: [AB_10670282](nif-antibody:AB_10670282){#intref0130}Anti-mouse CD49b (DX5)eBioscienceCat\#17-5971-82; RRID: [AB_469485](nif-antibody:AB_469485){#intref0135}Anti-mouse CD44 (IM7)eBioscienceCat\#17-0441-82; RRID: [AB_469390](nif-antibody:AB_469390){#intref0140}Anti-mouse α4β7 Integrin (DATK32)eBioscienceCat\#46-5887-82; RRID: [AB_2573793](nif-antibody:AB_2573793){#intref0145}Anti-mouse PD-1 (J43)BD BiosciencesCat\#565815; RRID: [AB_2739366](nif-antibody:AB_2739366){#intref0150}Anti-mouse Sca-1(D7)eBioscienceCat\#45-5981-82; RRID: [AB_914372](nif-antibody:AB_914372){#intref0155}Anti-mouse IL-13 (eBio13A)eBioscienceCat\#12-7133-82; RRID: [AB_763559](nif-antibody:AB_763559){#intref0160}Anti-mouse CD200R (OX-110)eBioscienceCat\#46-5201-82; RRID: [AB_10804765](nif-antibody:AB_10804765){#intref0165}Anti-mouse CD25 (PC61.5)eBioscienceCat\# 46-0251-82; RRID: [AB_2734935](nif-antibody:AB_2734935){#intref0170}Anti-mouse Flt3 (CD135) (A2F10)eBioscienceCat\#46-1351-82; RRID: [AB_10733393](nif-antibody:AB_10733393){#intref0175}Anti-mouse Eomes (Dan 11mag)eBioscienceCat\#46-4875-82; RRID: [AB_10597455](nif-antibody:AB_10597455){#intref0180}Anti-mouse Tbet (eBio4B10)eBioscienceCat\#50-5825-82; RRID: [AB_10596655](nif-antibody:AB_10596655){#intref0185}Anti-mouse Perforin (S16009B)BiolegendCat\#154404; RRID: [AB_2721465](nif-antibody:AB_2721465){#intref0190}Anti-mouse CD49a (Ha31/8)BD BiosciencesCat\#564862; RRID: [AB_2734135](nif-antibody:AB_2734135){#intref0195})Anti-mouse T1/ST2 (DJ8)MD BioproductsCat\#101001B; RRID: [AB_947551](nif-antibody:AB_947551){#intref0200}Anti-human/mouse/rat PLZF (D-9)Santa CruzCat\#sc-28319; RRID: [AB_2218941](nif-antibody:AB_2218941){#intref0205}**Chemicals, Peptides, and Recombinant Proteins**Collagenase IGIBCOCat\#17100-017DNase I, from bovine pancreasSigma-AldrichCat\#D5025/DN25Fixable Viability Dye eFluor780InvitrogenCat\#65-0865-14Liberase TL, research gradeRocheCat\#385040PBS (endotoxin-free)Sigma-AldrichCat\#D1408Fetal Calf SerumGIBCOCat\#10270-106PercollGE HealthcareCat\#17-0891-01HEPESGIBCOCat\#15630-0562-MercaptoethanolSigma-AldrichCat\#M6250RPMI 1640 + GlutaMAXGIBCOCat\#61870-010IMDMGIBCOCat\#31980-022Non-EAAGIBCOCat\#111040-050Protein Transport Inhibitor CocktailInvitrogenCat\#00-4980-93GolgiPlug™BD BiosciencesCat\#51-2301KZ16% Paraformaldehyde, Methanol-freeThermoScientificCat\#28906Foxp3 Staining KiteBioscienceCat\#00-5523-00Cytofix/Cytoperm Plus KitBD BiosciencesCat\#555028PMA (phorbol 12-myristate 13-acetate)Sigma-AldrichCat\#P8139IonomycinSigma-AldrichCat\#I0634rmIL-7, carrier-freeBiolegendCat\#577806rmSCF, carrier-freeBiolegendCat\#579706rmIL-2, carrier-freeBiolegendCat\#575406rmIL-15, carrier-freeBiolegendCat\#566304rmIL-18, carrier-freeBiolegendCat\#767006Agencourt AMPure XP beadsBeckman CoulterCat\#A63881**Critical Commercial Assays**Foxp3 staining kiteBioscienceCat\#00-5523-00Illumina Nextera XT DNA Library Preparation KitIlluminaCat\#C-131-1096Qubit dsDNA HS assay kitInvitrogenCat\#Q32851**Deposited Data**Single-cell RNA sequencing dataThis paperGEO accession number [GSE131038](ncbi-geo:GSE131038){#interref265}**Experimental Models: Cell Lines**JM8 ES cellsWelcome Sanger InstituteN/AMouse: OP9Sunnybrook Research Institute[@bib39]Mouse: OP9-DL1Sunnybrook Research Institute[@bib39]**Experimental Models: Organisms/Strains**Mouse: C57BL/6JOlaJackson Labs (Bred in LMB)Cat\#000664; RRID: IMSR_JAX:000664Mouse: CD45.1 *Rag2*^−/−^*Il2rgc*^−/−^Institute Pasteur[@bib38]Mouse: *Bcl11b*^*+/tdTom*^Sanger Institute[@bib23]Mouse: *Rorc*^*+/Kat*^MRC-LMBN/AMouse: *Id2*^*+/BFP*^MRC-LMBN/AMouse: *Gata3*^*+/hCD2*^MRC-LMBN/AMouse: *Rora*^*+/Teal*^MRC-LMBN/AMouse: *Zbtb16*^*tdTom*^MRC-LMBN/AMouse: *Id2*^*+/BFP*^*Gata3*^*+/hCD2*^*Rora*^*+/Teal*^*Bcl11b*^*+/tdTom*^ (4x polychromILC)MRC-LMBN/AMouse: *Id2*^*+/BFP*^*Gata3*^*+/hCD2*^*Rora*^*+/Teal*^*Bcl11b*^*+/tdTom*^*Rorc*^*+/Kat*^ (5x polychromILC)MRC-LMBN/A**Oligonucleotides**Primer: *Id2* target verification: F1 AAATGGG\
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Method Details {#sec4.3}
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### Mice {#sec4.3.1}

All mice were bred in a specific pathogen-free facility. In individual experiments, mice were matched for age, sex and background strain and all experiments undertaken in this study were done so with the approval of the UK Home Office. Bcl11b^tdTom^ mice were provided by Pentao Liu (Wellcome Sanger Institute, Cambridge, UK), CD45.1 *Rag2*^*−/−*^*Il2rgc*^*−/−*^ mice were a gift from James Di Santo and C57BL/6JOla mice were maintained in house.

### Generation of *Rorc*^Kat^ gene-targeted mice {#sec4.3.2}

*Rorc*^Kat^ mice were generated according to the strategy shown in [Figure S1](#mmc1){ref-type="supplementary-material"}A. Briefly, the gene encoding Katushka fluorescent protein, followed by a loxP-flanked Neomcyin cassette, was inserted directly downstream of the ATG start codon for the *Rorc* transcript. Successful targeting of JM8 ES cells was confirmed by Southern blot ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and the neomycin cassette was removed from the resultant mice by inter-crossing with a Cre recombinase strain. Genotyping was performed by quantitative PCR (see 'Primers').

### Generation of *Id2*^BFP^ gene-targeted mice {#sec4.3.3}

The *Id2* gene was targeted by standard homologous recombination in mouse JM8 ES cells. Appropriate homologous recombination of the *Id2*-blue fluorescent protein targeting construct was confirmed at the 3′ end by Southern blotting ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). At the 5′ end nested PCR using primers F1 and R1 followed by F2 and R2 was used to amplify a fragment which spanned from within the tagBFP sequence to beyond the end of the 5′ arm of homology. This fragment was then sequence verified. Genotyping was performed by quantitative PCR (see 'Primers').

### Generation of *Gata3*^hCD2^ gene-targeted mice {#sec4.3.4}

The *Gata3* was targeted by standard homologous recombination in mouse JM8 ES cells. Appropriate homologous recombination of the *Gata3*-human CD2 targeting construct was confirmed at the 5′ end by Southern blot analysis ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). At the 3′ side PCR using primers F1 and R1 was used to amplify a fragment which spanned from within the PGK-Neo cassette to beyond the end of the 3′ arm of homology. This fragment was then sequence verified. Genotyping was performed by quantitative PCR (see 'Primers').

### Generation of *Rora*^Teal^ gene-targeted mice {#sec4.3.5}

*Rora*^Teal^ mice were generated according to the strategy shown in [Figure S4](#mmc1){ref-type="supplementary-material"}A. Briefly, a reporter cassette, encoding a short Gly-Ser-Gly linker peptide, FLAG epitope tag, T2A self-cleaving peptide and Teal fluorescent protein, followed by a loxP-flanked neomcyin cassette, was inserted (directly upstream of the) *Rora* stop codon. Successful targeting of JM8 ES cells was confirmed by Southern blot analysis ([Figure S4](#mmc1){ref-type="supplementary-material"}B) and the neomycin cassette was removed from the resultant mice by inter-crossing with a Cre recombinase strain. Genotyping was performed by quantitative PCR (see 'Primers').

### Generation of *Zbtb16*^tdTom^ gene-targeted mice {#sec4.3.6}

The *Zbtb16* gene was targeted using CRISPR technology. Expression constructs encoding two guide RNA's of opposing orientation (G1 and G2) and the D10A nickase mutant of Cas9 were cotransfected into JM8 ES cells with the targeting construct shown in ([Figure S5](#mmc1){ref-type="supplementary-material"}A), to mediate insertion of the cassette by homology directed repair. Appropriate insertion was confirmed at both the 5′ and 3′ ends by PCR amplification of fragments spanning from within the PGK-Neo cassette to beyond the ends of the respective arms of homology using primers F1 and R1 (5′side) and F2 and R2 (3′side). These fragments were then sequence verified.

### Tissue preparation {#sec4.3.7}

Cell suspensions of spleen, MLN, liver and thymus were obtained by passing the tissues through a 70 μm strainer. Lung tissue was pre-digested with 750 U/mL collagenase I (GIBCO) and 0.3 mg/mL DNaseI (Sigma-Aldrich) prior to obtaining a single cell suspension. Bone marrow was removed from femurs, tibiae and hips by flushing with PBS + 2% FCS, or by centrifuging briefly at 6000 x g. For bone marrow, lung, liver and spleen cell suspensions, red blood cells were removed by incubation with RBC lysis solution (140 mM NH~4~Cl, 17 mM Tris; pH 7.2). Lung lymphocytes were further enriched by centrifugation in 30% percoll at 800 x g (GE Healthcare) while liver lymphocytes were enriched in 40% percoll at 690 x g.

For preparation of siLP lymphocytes, intestinal contents were removed by the application of gentle pressure along the length of the intestine. Intestines were opened longitudinally, cut into 3 cm long pieces and washed briefly by vortexing in PBS + 10 mM HEPES (PBS/HEPES). Epithelial cells were removed by incubation with RPMI supplemented with 2% FCS, 1 mM dithiothreitol and 5 mM EDTA for 2 × 20 min at 37°C with shaking (200 rpm). Intestinal pieces were washed with PBS/HEPES and incubated, with shaking, at 37°C with RPMI + 2% FCS, 0.125 KU/mL DNaseI (Sigma-Aldrich) and 62.5 μg/mL Liberase TL (Roche) until no large pieces of intestine remained. Cells were then passed through a 70 μm strainer, pelleted and separated over a 40%:80% gradient of Percoll at 600 x g for 20 min. siLP lymphocytes were isolated from the interface and prepared for flow cytometric analysis. Unless stated otherwise, small intestine lamina propria (siLP) includes associated Peyer's patches.

### Flow cytometry {#sec4.3.8}

Single cell suspensions were incubated with fluorochrome-, or biotin-, conjugated antibodies in the presence of anti-CD16/CD32 antibody (Fc block, clone 2.4G2), followed by fluorochrome-conjugated streptavidin where necessary. Antibodies were from Biolegend (CD3e (145-2C11), CD11b (M1/70), IL-7Rα (SB/199), CD62L (MEL-14), c-Kit (2B8), IL-5 (TRFK5), CCR6 (29-2L17), CD61 (HMβ3-1), MHCII (I-A/I-E, M5/144.15.2)); eBioscience (hCD2 (RPA-2.10), CD4 (GK1.5), CD5 (53-7.3), CD8 (53-6.7), CD19 (eBio1D3), NK1.1 (PK136), CD11c (N418), Gr-1 (RB6-8C5), FcεRI (MAR-1), Ter-119 (TER-119), CD45 (30-F11), KLRG1 (2F1), NKp46 (29A1.4), CD49b (DX5), CD44 (IM7), α4β7 integrin (DATK32), PD-1 (J43), Sca-1 (D7), IL-13 (eBio13A), CD200R1 (OX-110), CD25 (PC61.5), Flt3 (A2F10), Eomes (Dan11mag), Tbet (eBio4B10), perforin (S16009B), IFNγ (XMG1.2)); BD Biosciences (CD49a (Ha31/8)); MD Bioproducts (ST2 (DJ8)) and Santa Cruz (PLZF (D-9)). 'Lineage' staining included antibodies specific for CD3, CD4, CD5, CD8, CD11b, CD11c, CD19, FcεRI, Gr-1, NK1.1 and Ter-119 (although in some instances individual lineage markers were analyzed in separate channels, as indicated in figures). All samples were co-stained with a cell viability dye (Fixable dye eFluor780, Invitrogen) and analysis was performed on an LSRFortessa system (BD Biosciences). For cell sorting an iCyt Synergy (70 μm nozzle, Sony Biotechnology) was used. Intracellular transcription factor staining was performed by fixation with 2% PFA for 45 min, followed by incubation with fluorochrome antibodies diluted in perm wash buffer (Foxp3 staining kit, eBioscience). Intracellular cytokine was performed using BD Cytofix/Cytoperm Plus reagents (BD Biosciences) following pre-culture with RPMI, supplemented with 50 ng/mL phorbol 12-myristate 13-acetate (PMA), 500 ng/mL ionomycin and protein transport inhibitor (GolgiPlug®, BD Biosciences), for 4 h at 37°C.

### Adoptive transfers {#sec4.3.9}

Populations of mouse bone marrow cells were FACS purified into heat-inactivated mouse serum, diluted to 50% with PBS. Cell suspensions were aspirated with a syringe and implanted via tail vein injection into sublethally-irradiated (450 rad) *Rag2*^−/−^*Il2rgc*^−/−^ recipients. Analysis of donor cell progeny was performed 5 to 6 weeks after cell transfer.

### OP9 stromal cell co-cultures {#sec4.3.10}

OP9 cells were maintained in complete IMDM (IMDM, supplemented with 20% FCS, 1% penicillin, 1% streptomycin, 0.1% 2-mercaptoethanol and non-essential amino acids (GIBCO)). For progenitor cell co-culture, OP9 cells were incubated with 4 μg/mL mitomycin C for 2 h, washed, seeded at a density of 1 × 10^6^ cells per 96-well plate and allowed time to adhere. Sorted ILC progenitor populations were seeded onto OP9 monolayers and cultured in complete IMDM, supplemented with 25 ng/mL rmIL-7 (Biolegend) and 25 ng/mL rmSCF (Biolegend), for 7 days before flow cytometric analysis of progeny. For clonal analysis of progenitor cell potential, single cells were sorted directly onto OP9 monolayers and cultured in the presence of 25 ng/mL rmIL-7 and 25 ng/mL rmSCF for 14 - 19 days. Flow cytometric analysis was performed and wells were considered to be positive for a cell population if \> 3 cells appeared within the relevant gate. For analysis of perforin and IFN-γ expression cell subsets were seeded onto OP9 monolayers and cultured in complete IMDM, supplemented with 25 ng/mL rmIL-7 (Biolegend) and 25 ng/mL rmSCF (Biolegend), for 7 days and then stimulated with IL-2, IL-15 and IL-18 (all at 50 ng/mL) for 48 h before flow-cytometric analysis.

### Single cell RNA-sequencing and analysis {#sec4.3.11}

Single cell RNaseq libraries were prepared essentially as described previously ([@bib31]), with modifications as described below. Individual cells were flow cytometrically purified on a 96 well format into 0.2% Triton X-100 containing RNase inhibitor, dNTPs and oligo-dT primers and stored at −80°C. On thawing, lysates were heated to 72°C for 3 min and subject to reverse transcription, PCR preamplification (26 cycles) and PCR purification. cDNA library quality was assessed for all samples by qualitative PCR using primers for 18 s RNA with an additional check by Bioanalyzer using an Agilent high sensitivity DNA chip on a small subset of libraries. A subset of libraries was quantified using the Qubit dsDNA HS assay kit and an average value used to calculate library dilution to 100-150 pg/μl.

cDNA library tagmentation and amplification was performed using the Illumina Nextera XT DNA Library Preparation Kit according to manufacturer's instructions (except that all volumes were reduced to 25% of recommended volumes) and tagmentation performed at 55°C for 20 min. Nextera index and Illumina adaptor sequences were incorporated at the amplification stage (N7xx and S5xx). Amplified and indexed libraries were pooled and purified using Agencourt AMPure XP beads at a ratio of 1:0.9 library to beads and washed with 70% ethanol. Two rounds of purification were performed before a final elution in 1.25x total library volume of Nextera Resuspension buffer. Pooled indexed libraries were quantified using the Qubit dsDNA HS assay kit and this was confirmed by qPCR with adaptor specific primers. Quality was assessed by Bioanalyzer using an Agilent high sensitivity DNA chip. All pooled libraries had an average fragment length of between 500 and 800bp. Libraries were sequenced at the CRUK Cambridge NGS facility.

Reads were aligned to a modified mouse genome (v38.68), which had the 92 ERCC spike-ins added, using the Salmon pseudoaligner (v0.8.2) ([@bib30]). The resulting pseudocounts were then analyzed using R (v3.4.1) (<https://www.R-project.org/>) and the scater library (v1.6.3) ([@bib26]), scran library (v1.6.9) ([@bib25]), and sva library (sva: Surrogate Variable Analysis. R package v3.26.0). Cells with pseudocounts below 3 median-absolute-deviations away from the median were removed. The same threshold was applied to number of genes detected, percentage of counts mapping to mitochondrial genes and percentage of counts mapping to spike-ins. Genes with an average count across all remaining cells of less than 1 were removed. Size factors were then calculated using the scran library (based on the gene counts) and the data normalized by them, as described previously ([@bib25]). Finally, the batch effects caused by the use of different sequencing facilities were removed using the ComBat empirical Bayes framework from the sva library.

Highly variable genes were identified using the scran library, as described, with Local Polynomial Regression Fitting (loess) and alpha = 0.4. Only genes with FDR ≤ 0.05 and biological component of the variance \> = 0.5 were considered to be highly variable. Hierarchichal clustering was performed, based on the expression of these genes, using the hclust function with the ward.D2 method. Differential expression of genes between the clusters was identified using the findMarkers function from the scran library.

A heatmap was compiled for the expression of selected genes in those bone marrow cells that lacked Spi1, Sox13, or Gata1. Tree building was performed using the hclust function with the average method.

Pseudotime analysis was performed using the monocle library (v2.6.4) ([@bib33], [@bib34], [@bib40]). Only those bone marrow cells that did not express Spi1, Sox13, or Gata1 and that were sequenced at the CRUK (greater read depth) were selected (i.e., clusters C1-C3). Analysis was performed as described in the library documentation, with rho_threshold = 2 and delta_threshold = 8 for clustering.

### Statistical analysis {#sec4.3.12}

Statistical analysis was performed using GraphPad Prism v7.0b software.

Data and Software Availability {#sec4.4}
------------------------------

Single-cell RNA sequencing data have been deposited in the Gene Expression Omnibus under accession number GEO: [GSE131038](ncbi-geo:GSE131038){#interref0260}.
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